Kristen Riemenschneider represents life sciences companies, from global pharmaceutical companies to start-up biotechs, in a broad range of commercial and US Government transactions. Ms. Riemenschneider is nationally recognized for her work counseling life sciences and other companies that engage in US Government-funded research and development. In 2020, Ms. Riemenschneider represented several of the most high-profile vaccine manufacturers in their agreements to develop and deliver billions of doses of COVID-19 vaccines to the United States. Overall, she represented more than two dozen companies in negotiations with the US Government for COVID-19 countermeasure funding and support, with agencies including NIH, NCI, BARDA, NIAID and DoD.
More broadly, Ms. Riemenschneider's practice spans the full spectrum of commercial transactions and engages with all aspects of the biopharmaceutical product lifecycle. She represents companies in their most significant license and collaboration transactions, from research-stage, multi-target platform deals to single-product development deals, on behalf of both licensee and licensor. She has a deep technical understanding of life sciences products, and has negotiated a variety of manufacturing agreements for products with complex supply chains, such as autologous and allogeneic CAR-T products. She also represents a number of biotech companies in the negotiation of more routine commercial transactions, including clinical trial agreements, materials transfer agreements, and sponsored research agreements.
Ms. Riemenschneider has a degree in engineering and is a registered patent attorney. She also serves as a Founding Member of Chief DC, a network designed for senior women leaders to strengthen their leadership journey, cross-pollinate ideas across industries, and effect change from the top-down.
- AbbVie in a research collaboration and licensing agreement with Caribou Biosciences for Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy platforms. The transaction reflects a $40 million upfront cash and equity payment, an additional $300 million in payments upon achieving various development milestones, and royalties.
- AstraZeneca in agreements for the funding and global distribution of the University of Oxford's potential COVID-19 vaccine as well as the establishment of its global manufacturing and supply chain for the vaccine, including agreements with the US Biomedical Advanced Research and Development Authority (BARDA), Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance (Gavi), the Serum Institute of India (SII), and the governments of Germany, France, Italy, and the Netherlands.
- AstraZeneca, in the negotiation of an agreement for the development and supply of its COVID-19 long-acting antibody under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
- A global pharmaceutical company, in the negotiation of an agreement for the supply of a COVID-19 vaccine under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
- Numerous biotechnology and pharmaceutical companies in negotiations with HHS, BARDA, NIAID and other agencies for the government-supported research and development of COVID-19 diagnostics, therapeutics and vaccines.
- Sanofi in a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases for $150 million upfront and more than $2 billion in potential milestones plus royalties.
- AstraZeneca in the negotiation of a multi-target research collaboration with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases. The transaction reflected a deal value of $4 billion in development and sales milestones, as well as tiered high single digit to low double digit royalties.
- Novartis, in the negotiation of license and supply agreements with Spark Therapeutics for ex-US development and commercialization of Luxturna, the first approved gene therapy for an inherited disease. The transaction reflected a deal value of $170 million in achievable milestones as well as royalties.
- Novartis, in the negotiation of an investment with Blackstone for the formation of Anthos Therapeutics, and the related license of MAAA868, an anti-coagulant, to Anthos.
- Novartis, in the negotiation of a supply agreement for the EU production of Kymriah, the first CAR-T cell therapy approved by the United States Food and Drug Administration (FDA).
- Insmed Incorporated, in the negotiation of a license and collaboration agreement with AstraZeneca regarding an early-stage respiratory drug. The transaction reflected a deal value of $150 million in achievable milestones and double-digit royalties.
- Omada Health in a long-term strategic collaboration with Abbott Diabetes Care to integrate Abbott's continuous glucose monitoring (CGM) technology with Omada's professional coaching and digital care platform, aiming to create a new paradigm for people with Type 2 diabetes.
- Kongsberg Gruppen ASA in the sale of its underwater technology company Hydroid, Inc. for USD 350 million to Huntington Ingalls Industries (HII), the largest supplier of vessels to the US Navy, and the negotiation of a related strategic alliance agreement concerning underwater technology and maritime solutions.
- JD, University of Virginia School of Law
- BSEE, Electrical Engineering, University of Virginia
- District of Columbia
- US Patent and Trademark Office
- United States Court of Federal Claims, The Honorable Francis Allegra